Alvotech Eyeing US Aflibercept Biosimilar Approval This Year With FDA Acceptance

Alvotech welcomed the “advantage of our fully integrated approach and broad in-house capabilities in both R&D and manufacturing,” after the US Food and Drug Administration accepted for review its AVT06 proposed biosimilar to Eylea (aflibercept) 2mg, for which Teva will handle commercialization upon launch.